This author has yet to write their bio.Meanwhile lets just say that we are proud old admin contributed a whooping 84 entries.
HIGH IMPACT – During Roche’s HDSA presentation, the company discussed GENERATION-HD1 trial data and post-hoc analysis in subgroups of patients. The call was led by Peter McColgan (Roche) and Lauren Boak (Roche). The speaker mentioned that there were over 700 participants listening in to the talk. The GENERATION HD-1 study is a randomized, multi-center double-blind […]
HIGH IMPACT – Poseida announced in its Q3 press release that it will end its P-BCMA-101 autologous CAR-T program and prioritize its allogeneic CAR-T P-BCMA-ALLO1. “While we believe the P-BCMA-101 autologous program has competitive advantages and would be approvable, one long-term strategic benefit of that program has been to inform our highly-differentiated allogeneic approach. With […]
November 2, 2021 at 10:00 AM ET (sign up here) Please join us to review recent and upcoming clinical and regulatory developments in skin and auto-immune disease. Bloomberg Intelligence analyst Michael Shah, and Senior Principal of inThought Research Amanda Weyerbacher, PhD, will be joined by dermatologist Steven R. Feldman, MD, PhD and rheumatologist Christopher Ritchlin […]
June 9 at 11am – 12:30pm ET (sign up here) Please join us for a review of key data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Bloomberg Intelligence analysts Marc Engelsgjerd, MD, and Sam Fazeli, PhD, and inThought Research analyst Matt Presby, PhD, will be joined by expert speakers Patrick Forde, MBBCh, […]
HIGH IMPACT – Reata has submitted an NDA to the FDA for bardoxolone methyl for the treatment of chronic kidney disease caused by Alport Syndrome. Reata has requested priority review for the application. The submission was based on the results of the phase 2/3 CARDINAL study which demonstrated statistically significant improvement in kidney function as […]
